Search

Displaying results 2021 - 2030 of 10000 in total
  1. Drug

    Arbutin

    go.drugbank.com/drugs/DB11217
    Approved

    It is found in foods, over-the-counter drugs, and herbal dietary supplements [F43]. … Arbutin is available in both natural and synthetic forms; it can be synthesized from acetobromglucose and [DB09526] [F43].

  2. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone … that has demonstrated safe and effective therapy in both the adult and pediatric population.

  3. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … The phase II of the same study showed that in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (NSCLC), adagrasib was efficient without new safety signals.

    Synonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-
  4. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.

  5. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    [L39429] Baclofen was investigated for use in alcohol dependence and withdrawal; however, evidence is limited and there is inconsistent evidence to suggest its clinical efficacy in managing alcohol … Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients.

    Synonyms: DL-Baclofen, DL-4-Amino-3-p-chlorophenylbutanoic acidProducts: BACLOFEN 10 MG/ 20 ML, BACLOFEN 40 MG / 20 ML
  6. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway. … [A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.

  7. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.

  8. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    It is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself. … It can also be used as a rescue therapy if severe side effects present within 96 hours after initiation of therapy.

  9. Drug

    Curcuma xanthorrhiza oil

    go.drugbank.com/drugs/DB11265
    ApprovedNutraceutical

    _Curcuma xanthorrhiza_ oil is found as an active ingredient in cosmetic and hygienic products, and marketing of products containing _Curcuma xanthorrhiza_ oil is authorized in some European countries including … _Curcuma xanthorrhiza_ oil is extracted from _Curcuma xanthorrhiza_ Roxb., a member of the ginger family (_Zingiberaceae_) that is widely distributed in the region of Southeastern Asia [A33162].

    Synonyms: Temu lawak oil, Curcuma xanthorrhiza oil
  10. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    Infection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … conserved region of the GP<sub>1,2</sub> protein that is responsible for interacting with the host NPC1 protein to mediate EBOV endolysosomal escape, a key step in the EBOV lifecycle.